-
-
-
-
-
-
-
Myriad Genetics launches Prolaris + AI prostate cancer test
-
-
-
-
-
-
-
Myriad Genetics (MYGN) Tops Q3 EPS by 1c, Beats on Revenue; Offers FY25 Guidance
-
-
-
-
-
-
-
Piper Sandler: 'Opportunities to Buy Dislocated Stocks after Prints'
-
-
-
-
-
-
-
Piper Sandler Upgrades Myriad Genetics (MYGN) to Overweight
-
-
-
-
-
-
-
Myriad Genetics (MYGN) Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay
-
-
-
-
-
-
-
Myriad Genetics (MYGN) Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch
-
-
-
-
-
-
-
Scotiabank Reiterates Sector Outperform Rating on Myriad Genetics (MYGN)
-
439,035 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

